Our findings suggest a potential therapeutic role for JAK-STAT6 pathway inhibitors, which conceivably could treat both the epithelial inflammation and subepithelial fibrosis in patients with EoE. The gene discussed is STAT6; the disease is eosinophilic esophagitis.